Australia seems poised to experience potentially transformative treatment for obesity: Retatrutide. This new dual molecule – acting on both GLP-1 and GIP receptors – demonstrates significant outcomes in international studies, pointing to meaningful reductions in weight. While regulatory clearance hasn't occurred with the Therapeutic Goods Admin… Read More